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For clinical use, the diagnostic accuracy of demographic, sonographic and biochemical variables alone is poor. The risk of malignancy index (RMI) was developed by Jacobs et al. [9] for use in referral of relevant patients to gynecologic oncologic centers. The RMI was the first diagnostic model to combine demographic, sonographic and biochemical data in assessment of patients with pelvic masses. The risk of malignancy index is the product of the ultrasound scores (U), the menopausal score (M), and the absolute value of serum CA-125 levels: RMI=U × M × CA-125. The RMI, now termed RMI 1, was developed in the 1990s by Jacobs et al. [9] . Tingulstad et al. [10] developed their version of the RMI in 1996, which is now known as RMI 2. In 1999, Tingulstad et al. [11] modified the RMI, termed RMI 3. Yamamoto et al. [12] , who created their own model of a malignancy risk index, added the parameter of tumor size (S) to the RMI, and have termed it RMI 4. Retrospective and prospective validation of the four versions of the RMI have been conducted in different clinical studies [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] , where a cutoff value of 200 for RMI 1-3 and 450 for RMI 4 showed the best discrimination between benign and malignant pelvic masses, with high levels of sensitivity and specificity (sensitivity 51%-90%, specificity 51%-97%). The main advantage of four RMIs is that it is a simple scoring system that can be applied directly into clinical practice without the introduction of expensive or complicated methods (such as computed tomography scan, magnetic resonance imaging, and wholebody positron emission tomography). The RMIs can be applied in less specialized centers. The purpose of this study was to evaluate the ability of the four malignancy risk indices for discrimination of a benign mass from a malignant pelvic mass.
Materials and Methods
This is a retrospective study. Clinical data were obtained from 547 women with a pelvic mass, who were scheduled to undergo laparotomy and laparoscopy at the Department of Obstetrics and Gynecology of Inha University hospital between January, 2007, and December, 2010. Patients' preoperative serum CA-125 levels, ultrasound findings, and menopausal status were noted. Ultrasound was performed transvaginally using a 7.5 MHz transducer (Acuvix XQ, Medison, Korea) in all cases; an abdominal scan was also conducted when indicated. A score was assigned for the following ultrasound features, which are suggestive of malignancy: presence of a multilocular cystic lesion, solid areas, bilateral lesions, ascites, and intraabdominal metastases, which each received a score of one point. Thus, a total ultrasound score (U) was calculated for each patient. Ultrasound was performed for measurement of tumor size (S) for each patient. The ultrasounds were performed by gynecologic oncologists, general gynecologists, or residents (under the supervision of gynecologist). Postmenopausal status was defined as more than one year of amenorrhea or age older than 50 years in women who had undergone hysterectomy. All other women were considered premenopausal. Serum samples were collected preoperatively and measurement of serum CA-125 was performed using Electrochemiluminescence Immunoassaay (ECLIA). Based on the data obtained, RMI 1, RMI 2, RMI 3, and RMI 4 were calculated for all patients together with the sensitivity, specificity, diagnostic accuracy, and positive and negative predictive values of the four methods as follows: 1) RMI 1 (Jacobs et al. [9] , 1990)=U×M×CA-125, where a total ultrasound score of 0 made U=0, a score of 1 made U=1, and a score of ≥2 made U=3; premenopausal status made M=1 and postmenopausal M=3. The serum level of CA-125 was applied directly to the calculation. 2) RMI 2 (Tingulstad et al. [10] , 1996)=U×M×CA-125, where a total ultrasound score of 0 or 1 made U =1, and a score of ≥2 made U=4; premenopausal status made M=1 and postmenopausal M=4. The serum level of CA-125 was applied directly to the calculation. 3) RMI 3 (Tingulstad et al. [11] , 1999)=U×M×CA-125, where a total ultrasound score of 0 or 1 made U=1, and a score of ≥2 made U=3; premenopausal status made M=1 and postmenopausal M =3. The serum level of CA-125 was applied directly to the calculation. 4) RMI 4 (Yamamoto et al. [12] , 2009)=U×M×S (size in centimeters)×CA-125, where a total ultrasound score of 0 or 1 made U=1, and a score of ≥2 made U=4. Premenopausal status made M =1 and postmenopausal status made M=4. A tumor size (single greatest diameter) of <7 cm made S=1, and ≥7 cm made S=2. The serum level of CA-125 was applied directly to the calculation. The histopathologic diagnosis was regarded as the definitive outcome. Gynecological cancers were found staged according to the International Federation of Gynecology and Obstetrics (FIGO) classification [25] . Sensitivity was defined as the percentage of patients with malignant disease showing a positive test result. Specificity was defined as the percentage of patients with benign disease showing a negative test result. The positive predictive value was defined as the percentage of patients with a positive test result who had malignant disease and the negative predictive value was defined as the percentage of patients with a negative test result who had benign disease. Accuracy was defined as the percentage of all patients who had malignant disease with a positive test result and benign disease with a negative test result. The SPSS ver. 15.0 (SPSS Inc., Chicago, IL, USA) was used in performance of statistical analyses. The χ 2 -test was used for determination of differences in distribution of age, menopausal status, tumor size, and ultrasound score. The Mann-Whitney U-test was applied when testing differences in distribution of CA-125 among women with benign and malignant pelvic masses. McNemar's test was used when testing differences in performance between RMI 1, RMI 2, RMI 3, and RMI 4. A receiver operating characteristic (ROC) curve was created for demonstration of the relationship between sensitivity and specificity of CA-125, menopausal status, ultrasound score, tumor size, and RMI 1-4 in discrimination between benign and malignant pelvic masses.
Results
A total of 547 patients were included in the study; 434 patients (79.3%) were diagnosed with benign conditions, whereas 113 patients (20.7%) had malignant disease (Table 1) . Malignant tumors included serous cystadenocarcinoma (n=35), mucinous cystadenocarcinoma (n=13), endometrioid carcinoma (n=6), clear cell carcinoma (n=6), transitional cell carcinoma (n=7), granulosa cell tumor (n=6), Yolk sac tumor (n=2), dysgerminoma (n=2), immature teratoma (n=1), Sertoli-Leidig cell tumor (n=1), malignant mixed mullerian tumor (n=2), mullerian adenosarcoma (n=1), Krukenberg's tumor (n=2), and borderline malignancy (n=29). Benign gynecological conditions included mature cystic teratoma (n=184), mucinous cystadenoma (n=85), serous cystadenoma (n=93), endometriosis (n=27), fibroma (n=12), fibrothecoma (n=5), tuboovarian abscess (n=5), paratubal cyst (n=6), functional follicle (n=6), struma ovarii (n=3), actinomycosis (n=2), brenner tumor (n=2), sclerosing stromal tumor (n=1), and leiomyoma (n=1). Distribution of benign and malignant cases according to age, menopausal status, ultrasound score, tumor size, and CA-125 is shown in Table 2 . Results of univariate analysis showed a significant linear trend for malignancy according to increasing age, postmenopausal state, increasing ultrasound score, large tumor size, and increasing CA-125, respectively. When compared with women with benign disease, a significantly higher mean serum level of CA-125 was observed among women with (507 U/mL vs. 35 U/mL). Data for sensitivity, specificity, positive and negative predictive values, and diagnostic accuracy of different levels of serum CA-125, ultrasound score, tumor size, and menopausal status are reported in Table 3 . The best performance was obtained for a serum CA-125 level of 40 U/mL. At a serum level of CA-125 40 U/ mL, sensitivity for detection of malignancy was 73.4% and specificity was 83.1%, positive and negative predictive values were Values are presented as number (%).
for area under the curve for menopausal status, serum CA-125, ultrasound score, and tumor size were 0.5870, 0.8472, 0.9007, and 0.7714, respectively. The four RMIs showed statistical significance with menopausal status (P=0.001) and tumor size (P=0.03), but not with CA-125 and ultrasound score (P >0.05). Data on diagnostic performance of ultrasound score, CA-125, menopausal status, tumor size, RMI 1, RMI 2, RMI 3, and RMI 4 are shown in the receiver-operating characteristic curves (Fig. 1) .
Discussion
Management of the pelvic mass is a common and controversial clinical problem [26] . Malignant tumors should be referred to specialized centers for gynecologic oncologic surgery; therefore, differential diagnosis of benign from malignant tumors is essential in order to decide on the optimal approach in each case. The lack of screening tests for early diagnosis of ovarian cancer is an important determinant of the mortality rate from this disease. Due to the absence or subtlety of early symptoms, more than 70% of patients are diagnosed with advanced-stage ovarian cancer [27] . Four RMIs had some different characteristics. RMI 1 was the first version as developed by Jacobs et al. [9] and gave an ultrasound score (U) of 0 when none of the ultrasound features were present, resulting in an RMI 1 of 0 regardless of the CA-125 level. But, RMI 2-4 had not ultrasound score (U) of 0. Yamamoto et al. [12] have published their study in which RMI 4 was created, that includes tumor size as an additional parameter. Results of this study demonstrated the ability of four RMIs, ultrasound score, and serum CA-125 to correctly identify benign and malignant pelvic masses. The RMI was originally developed by Jacobs et al. [9] , and, subsequently, the same group reproduced the results in a new group of patients, establishing the superiority of RMI over the individual parameter [13] . However, in the present study, four RMIs showed statistical significance with menopausal status and tumor size, but not with CA-125 and ultrasound score. This study has not established the superiority of the four RMIs over the use of CA-125 and ultrasound score, and there was no necessity for using four RMIs instead of CA-125 and ultrasound score.
Findings from the present study demonstrated that the overall best performance in RMI 1 and RMI 3 was obtained at a cut-off level of 150, and at 200 for RMI 2, and 400 for RMI 4. Many authors have suggested a cut-off value for RMI 1-3 of 200 [9] [10] [11] 16, 18] . Using tumor size, Yamamoto et al. [12] developed their own RMI, Jung-Woo Park, et al. Four RMIs in pelvic masses and named it RMI 4 (using a cutoff level of 450). Using a cutoff of 120, Clarke et al. [28] reported a sensitivity of 72% and a specificity of 87% for RMI 1; RMI 2 showed a sensitivity of 76% and a specificity of 81%; RMI 3 showed a sensitivity of 74% and a specificity of 84%. The lower cut-off values for RMI 1, RMI 3, and RMI 4, obtained in our study may be associated with the higher number of malignant cases in the premenopausal group-56.6% versus 19% [9] , and 20% [10] .
In our study, we found no statistically significant difference in performance of these four different RMIs for identification of malignancy. However, other investigators have reported that RMI 2 is more reliable in discriminating between benign and malignant disease [10, 14] . Tingulstad et al. [10] developed their RMI in 1996 and named it RMI 2. In a direct comparison of their RMI with that developed by Jacobs et al. [9] , they found that, at a cut-off level of 200, RMI 2 was significantly better than RMI 1 for prediction of malignancy (McNemar test, P =0.001). Morgante et al. [14] also reported a similar observation that for all cut-off values between 80 and 250, RMI 2 showed better performance than RMI 1 (P=0.0001). In our study, we observed sensitivity and specificity of 79.6% and 79.9% at a cut-off level of 200 for RMI 2. Tingulstad et al. [11] , who modified the RMI (defined RMI 3), observed that, at a cut-off level of 200, sensitivity and specificity were 71% and 92%, respectively. In our study on application of this modified RMI (RMI 3), we observed a sensitivity and specificity of 77.9% and 81.1% at a cut-off level of 150, respectively, which is comparable with results reported by Tingulstad et al. [11] .
Results of a study conducted by Manjunath et al. [16] in 2001, which compared RMI 1, RMI 2, and RMI 3, confirmed that there was no statistical difference in benign -malignancy discrimination between these three indices. Results of a study conducted by Aktürk et al. [24] in 2011, which compared RMI 1, RMI 2, RMI3, and RMI 4, confirmed that there was no statistical difference in benign-malignancy discrimination between these four indices. In 2009, Yamamoto et al. [12] developed their own RMI 4, and confirmed that, at a cut-off level of 450, the accuracy of RMI 4 was better than that of RMI 1, RMI 2, and RMI 3, with a cutoff level of 200. They reported that at a cutoff level of 450, sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were 86.8%, 91.0%, 63.5%, 97.5%, and 90.4%, respectively [12] . In our study, we observed a sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 77.9%, 85.9%, 59.1%, 93.7%, and 84.3% at a cutoff level of 400 for RMI 4, respectively, which is comparable with results reported by Yamamoto et al. [12] . However, we also found that the other three indices showed reliable diagnostic performance, which differed from the results of Yamomoto et al. [12] . In assessment of the results of this study, some limitations should be considered. First, clinical data obtained retrospectively from a single institution. Second, training and skill of ultrasonologists should be taken into account.
In conclusion, four RMIs (cutoff level at 150 of RMI 1 and RMI 3, at 200 of RMI 3, and at 400 of RMI 4) were found to be statistically significant diagnostic criteria, compared with menopausal status and tumor size, which can discriminate between benign and malignant pelvic masses.
